Restless Legs Syndrome: Challenges to Treatment

Area of Science:

• Neurology
• Pharmacology

Background:

• Dopaminergic treatment (DT) was the standard for restless legs syndrome (RLS).
• While effective short-term, DT can lead to augmentation, tolerance, and impulse control disorders long-term.
• Iron deficiency is a common comorbidity and potential factor in RLS.

Purpose of the Study:

• To review current and emerging treatments for restless legs syndrome.
• To highlight the limitations of long-term dopaminergic therapy.
• To discuss alternative and novel therapeutic strategies for RLS management.

Main Methods:

• Literature review of RLS treatment guidelines and emerging therapies.
• Analysis of the efficacy and safety profiles of different RLS medications.
• Discussion of the role of iron management in RLS.

Main Results:

• Alpha-2 ligands are recommended as first-line RLS treatment, especially without prior DT.
• Opioids, like oxycodone extended-release with naloxone, are approved as second-line options in Europe.
• Perampanel and dipyridamole show promise as novel non-dopaminergic treatments.

Conclusions:

• Current RLS treatment guidelines favor alpha-2 ligands over long-term DT.
• Monitoring and correcting brain iron levels are crucial during RLS treatment.
• Further research into novel non-DTs is warranted for improved RLS management.